Item 8.01. Other Events.
On January 6, 2023, Novan, Inc. (the "Company") issued a press release
announcing the submission of a New Drug Application to the U.S. FDA for
Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum. The
full text of the Company's press release is filed as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by reference.
On January 6, 2023, the Company also published a corporate presentation on its
website at www.Novan.com. The corporate presentation is filed as Exhibit 99.2 to
this Current Report and is incorporated herein by reference.
© Edgar Online, source Glimpses